Literature DB >> 6828080

Muscle proteolysis induced by a circulating peptide in patients with sepsis or trauma.

G H Clowes, B C George, C A Villee, C A Saravis.   

Abstract

Accelerated proteolysis of muscle is characteristic in patients with trauma or sepsis, but its cause is not well understood. Using rat muscle in vitro, we developed a bioassay to compare the proteolytic activity of plasma from 50 patients with trauma or sepsis with that of plasma from 14 normal volunteers and from 15 patients who had undergone "clean" elective surgical procedures. The mean proteolytic activity in the plasma of patients with trauma or sepsis was found to be 190 +/- 8.0 per cent of the control value (rat muscle incubated in medium alone), whereas the activity in normal plasma was 124 +/- 4.5 per cent (P less than 0.001). The activity in the plasma of patients who had undergone elective surgery was slightly elevated at 142 +/- 2.5 per cent (P less than 0.005). In 25 of the patients with trauma or sepsis the rate of amino acid release from one leg was measured by subtracting the concentration of tyrosine plus phenylalanine in the femoral artery plasma from that in the femoral vein; this rate correlated well with the bioactivity of the plasma in the bioassay system (r = 0.67, P less than 0.001). By means of ultrafiltration and chromatography, the plasma factor inducing proteolysis was isolated and found to be a peptide, probably containing sialic acid, with a chain of 33 amino acids and a molecular weight of approximately 4274 daltons.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6828080     DOI: 10.1056/NEJM198303103081001

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  74 in total

1.  Nutrition in the surgical patient.

Authors:  J A Vestrup
Journal:  Can J Anaesth       Date:  1987-05       Impact factor: 5.063

2.  Myositis due to Salmonella enteritidis bacteremia.

Authors:  A E Studemeister; H P Kaplan
Journal:  West J Med       Date:  1989-07

Review 3.  [Cellular regulation of anabolism and catabolism in skeletal muscle during immobilisation, aging and critical illness].

Authors:  Eva-Maria Strasser; Barbara Wessner; Erich Roth
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

Review 4.  Regulation of protein turnover in skeletal and cardiac muscle.

Authors:  P H Sugden; S J Fuller
Journal:  Biochem J       Date:  1991-01-01       Impact factor: 3.857

Review 5.  Hypermetabolism and Nutritional Support in Sepsis.

Authors:  John C Alverdy
Journal:  Surg Infect (Larchmt)       Date:  2018-02-02       Impact factor: 2.150

6.  A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance.

Authors:  J E Parrillo; C Burch; J H Shelhamer; M M Parker; C Natanson; W Schuette
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

7.  Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation.

Authors:  R Roubenoff; R A Roubenoff; J G Cannon; J J Kehayias; H Zhuang; B Dawson-Hughes; C A Dinarello; I H Rosenberg
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

8.  Chronic Escherichia coli infection induces muscle wasting without changing acetylcholine receptor numbers.

Authors:  Christiane G Frick; Heidrun Fink; Maria L Gordan; Barbara Eckel; J A Jeevendra Martyn; Manfred Blobner
Journal:  Intensive Care Med       Date:  2007-10-20       Impact factor: 17.440

9.  The effects of endotoxaemia on protein metabolism in skeletal muscle and liver of fed and fasted rats.

Authors:  M M Jepson; J M Pell; P C Bates; D J Millward
Journal:  Biochem J       Date:  1986-04-15       Impact factor: 3.857

10.  Antibodies of predetermined specificity to the major charged species of human interleukin 1.

Authors:  G Limjuco; S Galuska; J Chin; P Cameron; J Boger; J A Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.